JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
Volume 17, Issue 3 (2025)
Iran J War Public Health 2025, 17(3): 1001-1009 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2025/10/6 | Accepted: 2025/10/22 | Published: 2025/07/19
Received: 2025/10/6 | Accepted: 2025/10/22 | Published: 2025/07/19
How to cite this article
Osamah N. Wennas, Maryam Haji Ghasem Kashani, Elaheh Abiri, Dhiya Altememy. Investigating the apoptotic effect of Schiff's base compounds derived from 2-hydroxynaphthaldehyde and 2-chloroethylamine, as well as manganese complexes, on HepG2 cells. Iran J War Public Health 2025; 17 (3) :1001-1009
URL: http://ijwph.ir/article-1-1680-en.html
URL: http://ijwph.ir/article-1-1680-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- , KASHANI@du.ac.ir
Abstract (154 Views)
Background: Schiff bases are compounds that have anti-cancer properties. The combination of Schiff bases with metals increases their anticancer properties.
Aim: The current study was conducted to determine the apoptotic effect of Schiff base compounds derived from 2-hydroxynaphthaldehyde and 2-chloroethylamine and manganese complexes on HepG2 cells compared to mesenchymal stem cells in the Damghan Faculty of Chemistry, Iran.
Methods: In this study, three Schiff base compounds, naph br, naph(br)2mn, and naph(br)2ni, were used to investigate anticancer properties on HepG2 cancer cells and compare them with adipose tissue mesenchymal stem cells (ASC). HepG2 and ASC cancer cells were treated for 24 hours with these chemicals at concentrations of 100 µM, 200 µM, 300 µM, 400 µM, 500 µM, 600 µM, and 700 µM. Cell proliferation and survival were evaluated by hemocytometry, MTT, and Ki-67 immunocytochemistry methods.
Results: Schiff base compounds can reduce the proliferation rate of HepG2 cancer cells and ASC at concentrations of 200, 300 µM, 400 µM, and 500 µM, and increase their rate compared to the control group.
Conclusion: Schiff base compounds can prevent the proliferation of cancer cells and induce apoptosis in multiple concentrations, showing their versatility and power in fighting cancer. By including these compounds in treatment methods, the effectiveness of current treatments can be increased, and drug resistance in cancer patients can be overcome. Health policymakers are encouraged to support the development and integration of these compounds into cancer treatment protocols to enhance patient care and foster advancements in the field of oncology.
Aim: The current study was conducted to determine the apoptotic effect of Schiff base compounds derived from 2-hydroxynaphthaldehyde and 2-chloroethylamine and manganese complexes on HepG2 cells compared to mesenchymal stem cells in the Damghan Faculty of Chemistry, Iran.
Methods: In this study, three Schiff base compounds, naph br, naph(br)2mn, and naph(br)2ni, were used to investigate anticancer properties on HepG2 cancer cells and compare them with adipose tissue mesenchymal stem cells (ASC). HepG2 and ASC cancer cells were treated for 24 hours with these chemicals at concentrations of 100 µM, 200 µM, 300 µM, 400 µM, 500 µM, 600 µM, and 700 µM. Cell proliferation and survival were evaluated by hemocytometry, MTT, and Ki-67 immunocytochemistry methods.
Results: Schiff base compounds can reduce the proliferation rate of HepG2 cancer cells and ASC at concentrations of 200, 300 µM, 400 µM, and 500 µM, and increase their rate compared to the control group.
Conclusion: Schiff base compounds can prevent the proliferation of cancer cells and induce apoptosis in multiple concentrations, showing their versatility and power in fighting cancer. By including these compounds in treatment methods, the effectiveness of current treatments can be increased, and drug resistance in cancer patients can be overcome. Health policymakers are encouraged to support the development and integration of these compounds into cancer treatment protocols to enhance patient care and foster advancements in the field of oncology.
Send email to the article author